Teva Pharmaceutical Industries ADR
(TEVA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,418,000 | -1,959,000 | -615,000 | -2,499,000 | 456,000 |
| Depreciation Amortization | 1,002,000 | 1,059,000 | 1,153,000 | 1,308,000 | 1,330,000 |
| Income taxes - deferred | -671,000 | -634,000 | -317,000 | -1,064,000 | -120,000 |
| Accounts receivable | -173,000 | 245,000 | 12,000 | 334,000 | N/A |
| Other Working Capital | -1,366,000 | -435,000 | -72,000 | 1,355,000 | -1,701,000 |
| Other Operating Activity | 1,439,000 | 2,971,000 | 1,207,000 | 2,156,000 | 833,000 |
| Operating Cash Flow | $1,649,000 | $1,247,000 | $1,368,000 | $1,590,000 | $798,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -467,000 | -455,000 | -458,000 | -480,000 | -251,000 |
| Net Acquisitions | N/A | -15,000 | N/A | -7,000 | N/A |
| Purchase Of Investment | -57,000 | -71,000 | -46,000 | -1,000 | -47,000 |
| Sale Of Investment | 42,000 | 40,000 | N/A | 4,000 | 172,000 |
| Other Investing Activity | 1,219,000 | 1,293,000 | 1,472,000 | 1,140,000 | 1,649,000 |
| Investing Cash Flow | $737,000 | $792,000 | $968,000 | $656,000 | $1,523,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 700,000 | N/A | 700,000 |
| Debt Issued | 2,298,000 | N/A | 2,451,000 | N/A | 4,974,000 |
| Debt Repayment | -4,112,000 | -1,641,000 | -4,152,000 | -1,369,000 | -7,140,000 |
| Common Stock Repurchased | -38,000 | -64,000 | N/A | N/A | N/A |
| Dividend Paid | -340,000 | -78,000 | N/A | N/A | N/A |
| Other Financing Activity | 41,000 | -8,000 | -912,000 | -118,000 | -706,000 |
| Financing Cash Flow | $-2,151,000 | $-1,791,000 | $-1,913,000 | $-1,487,000 | $-2,172,000 |
| Exchange Rate Effect | 21,000 | -174,000 | -30,000 | -123,000 | -128,000 |
| Beginning Cash Position | 3,300,000 | 3,227,000 | 2,834,000 | 2,198,000 | 2,177,000 |
| End Cash Position | 3,556,000 | 3,300,000 | 3,227,000 | 2,834,000 | 2,198,000 |
| Net Cash Flow | $256,000 | $73,000 | $393,000 | $636,000 | $21,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,649,000 | 1,247,000 | 1,368,000 | 1,590,000 | 798,000 |
| Capital Expenditure | -501,000 | -498,000 | -526,000 | -548,000 | -562,000 |
| Free Cash Flow | 1,148,000 | 749,000 | 842,000 | 1,042,000 | 236,000 |